PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME
申请人:ELI LILLY AND COMPANY
公开号:EP1121125A1
公开(公告)日:2001-08-08
US6087378A
申请人:——
公开号:US6087378A
公开(公告)日:2000-07-11
US6258826B1
申请人:——
公开号:US6258826B1
公开(公告)日:2001-07-10
[EN] PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME<br/>[FR] FORMULATIONS PHARMACEUTIQUES DE TRAITEMENT DU SYNDROME DE CARENCE OESTROGENIQUE
申请人:LILLY CO ELI
公开号:WO2000021535A1
公开(公告)日:2000-04-20
Formulations and applications thereof are described which are useful for the inhibition of various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of structure (I) in combination with compounds of formula (II) where X, Y, R, R', R?6, R7, and R8¿ are as defined herein.